La prevenzione delle infezioni da virus respiratorio sinciziale nei late preterm

Marcello Lanari; Paolo Bottau; Michela Silvestri; Giovanni A. Rossi

La prevenzione delle infezioni da virus respiratorio sinciziale nei late preterm

Translated title of the contribution: Prevention of respiratory syncytial virus infections in late preterm newborns

Marcello Lanari, Paolo Bottau, Michela Silvestri, Giovanni A. Rossi

Istituto "Giannina Gaslini"

Research output: Contribution to journal › Article › peer-review

Abstract

Late preterm infants (34-36 weeks' gestation) are more susceptible to infection by respiratory syncytial virus (RSV) because of the immaturity of both the respiratory and the immune system. Prevention of RSV infections is based on environmental avoidance and passive immunoprophylaxis with palivizumab, a specific anti-RSV humanized monoclonal antibody, proven to be effective in reducing the overall hospitalization rate for RSV-induced bronchiolitis in preterm newborns. The American Academy of Pediatrics has been recently updated the prophylaxis guidelines for newborns 33-35 weeks' gestation. Nevertheless some considerations are due for application of those new guidelines in our countries.

Translated title of the contribution	Prevention of respiratory syncytial virus infections in late preterm newborns
Original language	Italian
Pages (from-to)	15-20
Number of pages	6
Journal	Area Pediatrica
Volume	12
Issue number	1
Publication status	Published - Feb 2011

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Prevention of respiratory syncytial virus infections in late preterm newborns'. Together they form a unique fingerprint.

Cite this

@article{a34840ed49a74c2090a37b932462b8cb,

title = "La prevenzione delle infezioni da virus respiratorio sinciziale nei late preterm",

abstract = "Late preterm infants (34-36 weeks' gestation) are more susceptible to infection by respiratory syncytial virus (RSV) because of the immaturity of both the respiratory and the immune system. Prevention of RSV infections is based on environmental avoidance and passive immunoprophylaxis with palivizumab, a specific anti-RSV humanized monoclonal antibody, proven to be effective in reducing the overall hospitalization rate for RSV-induced bronchiolitis in preterm newborns. The American Academy of Pediatrics has been recently updated the prophylaxis guidelines for newborns 33-35 weeks' gestation. Nevertheless some considerations are due for application of those new guidelines in our countries.",

keywords = "Late preterm, Palivizumab, Recommendations, Respiratory syncytial virus",

author = "Marcello Lanari and Paolo Bottau and Michela Silvestri and Rossi, {Giovanni A.}",

year = "2011",

month = feb,

language = "Italian",

volume = "12",

pages = "15--20",

journal = "Area Pediatrica",

issn = "1591-0075",

publisher = "Masson SpA",

number = "1",

}

TY - JOUR

T1 - La prevenzione delle infezioni da virus respiratorio sinciziale nei late preterm

AU - Lanari, Marcello

AU - Bottau, Paolo

AU - Silvestri, Michela

AU - Rossi, Giovanni A.

PY - 2011/2

Y1 - 2011/2

N2 - Late preterm infants (34-36 weeks' gestation) are more susceptible to infection by respiratory syncytial virus (RSV) because of the immaturity of both the respiratory and the immune system. Prevention of RSV infections is based on environmental avoidance and passive immunoprophylaxis with palivizumab, a specific anti-RSV humanized monoclonal antibody, proven to be effective in reducing the overall hospitalization rate for RSV-induced bronchiolitis in preterm newborns. The American Academy of Pediatrics has been recently updated the prophylaxis guidelines for newborns 33-35 weeks' gestation. Nevertheless some considerations are due for application of those new guidelines in our countries.

AB - Late preterm infants (34-36 weeks' gestation) are more susceptible to infection by respiratory syncytial virus (RSV) because of the immaturity of both the respiratory and the immune system. Prevention of RSV infections is based on environmental avoidance and passive immunoprophylaxis with palivizumab, a specific anti-RSV humanized monoclonal antibody, proven to be effective in reducing the overall hospitalization rate for RSV-induced bronchiolitis in preterm newborns. The American Academy of Pediatrics has been recently updated the prophylaxis guidelines for newborns 33-35 weeks' gestation. Nevertheless some considerations are due for application of those new guidelines in our countries.

KW - Late preterm

KW - Palivizumab

KW - Recommendations

KW - Respiratory syncytial virus

UR - http://www.scopus.com/inward/record.url?scp=79955372139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955372139&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:79955372139

VL - 12

SP - 15

EP - 20

JO - Area Pediatrica

JF - Area Pediatrica

SN - 1591-0075

IS - 1

ER -